0001739614-24-000009.txt : 20240306 0001739614-24-000009.hdr.sgml : 20240306 20240306164125 ACCESSION NUMBER: 0001739614-24-000009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240304 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Deck Kelly CENTRAL INDEX KEY: 0001819427 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 24726547 MAIL ADDRESS: STREET 1: C/O INHIBRX, INC. STREET 2: 11099 N. TORREY PINES ROAD, SUITE 280 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824257312 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 4 1 wk-form4_1709761273.xml FORM 4 X0508 4 2024-03-04 0 0001739614 Inhibrx, Inc. INBX 0001819427 Deck Kelly C/O INHIBRX, INC. 11025 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 0 1 0 0 Chief Financial Officer 0 Stock Option (right to buy) 23.30 2024-03-04 4 M 0 8125 35.60 D 2033-01-03 Common Stock 8125 21875 D Stock Option (right to buy) 33.63 2024-03-04 4 M 0 53958 35.40 D 2031-01-15 Common Stock 53958 16042 D Stock Option (right to buy) 34.16 2024-03-05 4 M 0 10417 35.72 D 2032-01-11 Common Stock 10417 9583 D Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 11, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. /s/ Kelly Deck 2024-03-06